東生華製藥股份有限公司
東生華製藥股份有限公司在台灣開發並行銷醫藥產品。提供心血管、中樞神經及胃腸道等領域的處方藥。此外提供 MPap 甲基化偵測技術、AlphaLiquid 系列液態切片檢測（用於固體腫瘤病患的 MRD 監控與追蹤）、UNITED 基因檢測（偵測 DNA/RNA 臨床相關變異及 MSI/TMB 生物標記）以及乳癌測試。公司為台灣東洋藥品之子公司，成立於 1999 年，總部位於台灣台北市。
該股 RSI(6) 為 62.5，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日、60日均線，跌破120日均線。KD 指標中性（K=75.2）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | -2 | 0 | 0 | -2 |
| 08-07 | -3 | 0 | 0 | -3 |
| 08-06 | +14 | 0 | 0 | +14 |
| 08-05 | +10 | 0 | 0 | +10 |
| 08-04 | -1 | 0 | 0 | -1 |
| 08-03 | -2 | 0 | +2 | -2 |
| 07-31 | -9 | 0 | 0 | -13 |
| 07-30 | 0 | 0 | 0 | 0 |
| 07-29 | +3 | 0 | +8 | +6 |
| 07-28 | 0 | 0 | +6 | +1 |
| 07-27 | +2 | 0 | 0 | +2 |
| 07-24 | -3 | 0 | 0 | -3 |
| 07-23 | +2 | 0 | 0 | +2 |
| 07-22 | +4 | 0 | 0 | +4 |
| 07-21 | +3 | 0 | 0 | +3 |
| 07-20 | 0 | 0 | 0 | 0 |
| 07-17 | +4 | 0 | +2 | +5 |
| 07-16 | -3 | 0 | 0 | -3 |
| 07-15 | 0 | 0 | 0 | 0 |
| 07-14 | -5 | 0 | 0 | -5 |
| 07-13 | 0 | 0 | 0 | 0 |
| 07-09 | +4 | 0 | 0 | +4 |
| 07-08 | 0 | 0 | +10 | 0 |
| 07-07 | -1 | 0 | 0 | -1 |
| 07-06 | -5 | 0 | 0 | -5 |
| 07-03 | -3 | 0 | 0 | -3 |
| 07-02 | +1 | 0 | 0 | +1 |
| 07-01 | +3 | 0 | +9 | +3 |
| 06-30 | +3 | 0 | 0 | +3 |
| 06-29 | -5 | 0 | 0 | -5 |
| 06-26 | +5 | 0 | 0 | 0 |
| 06-25 | -3 | 0 | +2 | -2 |
| 06-24 | 0 | 0 | 0 | 0 |
| 06-23 | -6 | 0 | 0 | -6 |
| 06-22 | -1 | 0 | 0 | -1 |
| 06-18 | -1 | 0 | 0 | -1 |
| 06-17 | +3 | 0 | 0 | +3 |
| 06-16 | -3 | 0 | 0 | -3 |
| 06-15 | -2 | 0 | +5 | +3 |
| 06-12 | -5 | 0 | +2 | -5 |
| 06-11 | -12 | 0 | 0 | -12 |
| 06-10 | -6 | 0 | 0 | -6 |
| 06-09 | -6 | 0 | 0 | -6 |
| 06-08 | -3 | 0 | +2 | -5 |
| 06-05 | 0 | 0 | +1 | 0 |
| 06-04 | +2 | 0 | 0 | +2 |
| 06-03 | +11 | 0 | 0 | +11 |
| 06-02 | +10 | 0 | 0 | +10 |
| 06-01 | 0 | 0 | +8 | 0 |
| 05-29 | -3 | 0 | 0 | -3 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 1.08 億 | -0.4% | +27.4% |
| 2026/03 | 1.09 億 | +55.5% | +15.6% |
| 2026/02 | 6997 萬 | -34.6% | -35.9% |
| 2026/01 | 1.07 億 | +1.3% | +27.7% |
| 2025/12 | 1.06 億 | -10.4% | +4.2% |
| 2025/11 | 1.18 億 | -16.7% | +28.3% |
| 2025/10 | 1.42 億 | -41.6% | +45.0% |
| 2025/09 | 2.43 億 | +154.6% | +9.2% |
| 2025/08 | 9535 萬 | +12.8% | +7.4% |
| 2025/07 | 8452 萬 | -6.6% | +9.7% |
| 2025/06 | 9046 萬 | -3.5% | +30.0% |
| 2025/05 | 9376 萬 | - | +3.3% |